Navigation Links
Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
Date:10/6/2010

PARSIPPANY, N.J., Oct. 6 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA™ (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue of the peer-reviewed journal, Obstetrics & Gynecology.  The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.  It is estimated that up to 22 million women suffer from HMB in the U.S.(1,2)

In the double-blind, placebo-controlled 6-month study, women ages 18-49 years with HMB, defined as mean menstrual blood loss of 80 mL or more per cycle, were randomized to receive LYSTEDA (3.9 g/d) (n=115) or placebo (n=72) for up to 5 days per menstrual cycle through six cycles.  The LYSTEDA group had a significantly greater reduction in menstrual blood loss of 69.6 mL (40.4%) compared with 12.6 mL (8.2%) in the placebo group (p<.001).  This reduction in menstrual blood loss was considered meaningful to women.  Women taking LYSTEDA also experienced significant improvements in limitations in social, leisure and physical activities, measured using the Menorrhagia Impact Questionnaire (MIQ), a validated patient-reported outcome instrument, to measure changes at baseline and after three treatment menstrual cycles.

LYSTEDA was generally well tolerated, and the majority of adverse events were mild to moderate in severity.  The most common adverse events reported were menstrual discomfort or cramps, headache, and back pain.

"We are excited by the results of this clinical trial.  Women receiving LYSTEDA met all three primary efficacy points: a significantly greater reduction in menstrual blood loss compared with placebo, a reduction exceeding a pre-specified volume, and most importantly, a reduction
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientifics Urology/Gynecology Products Featured in Studies at Global Congress
2. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
3. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
4. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
5. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
8. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
9. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
10. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
11. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  For over a decade ... no link between vaccines and autism. But at least for ... In a statement , William Thompson , ... information" linking the MMR vaccine to an increased risk of ... of the same data suggests that African American males have ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue:  Drug Discovery Technologies - A ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The development of new ... requires extensive expenditure, in addition to consuming a ... a new drug involves the utilizing high-throughput screening ...
Breaking Medicine Technology:CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14
... Dec. 21, 2011  Shareholders of Medco Health Solutions, Inc. (NYSE: ... Express Scripts. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) ... vote present in person or by proxy at a special ... Merger dated July 20, 2011 by a margin of 99 ...
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
Cached Medicine Technology:Medco Shareholders Approve Merger With Express Scripts 2Actavis to Launch Novel Pain Medication in the US 2Actavis to Launch Novel Pain Medication in the US 3
(Date:9/2/2014)... N.J. (PRWEB) September 02, 2014 ... technologies and development solutions for drugs, biologics and ... of its strategic partner, Eli Lilly’s growth, it ... packaging lines at its Philadelphia Clinical Supply Center ... syringe packaging capabilities in its clinical supply facility ...
(Date:9/2/2014)... The performance of the Lotteries ... years. Industry revenue is estimated to grow at a ... through 2014-15, following stabilised growth over the past three ... alternate forms of gambling. Horse and sports betting, poker ... all become increasingly popular over the past five years, ...
(Date:9/2/2014)... Based on new studies, concerns ... kidney and spleen surgeries, have continued to mount. ... patients. , An article in the "Public ... Titilope Oduyebo and Bradley J. Quade called, "Peritoneal ... on Nov 26, 2012 defines a morcellator ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... announces that Class Counsel has filed an application ... awards in the class action litigation brought over ... LLP, the Court-Appointed Class Counsel in this litigation ... Bernstein, LLP; Audet & Partners, LLP; Levin Fishbein, ...
Breaking Medicine News(10 mins):Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 2Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 3Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3
... a brain cancer death sentence. It is the most lethal ... are diagnosed with GBM annually in the U.S., half ... within 3 years. The treatments include highly invasive surgeries to ... dose, both leading to a very low quality of life. ...
... conducted by the University of Michigan’s researchers has revealed that those ... unsafe are likely to put on weight. As many as 16% ... in the US are reported to be overweight, while in the ... tripled since the early 1990s. ,The researchers, led ...
... one more reason to raise a toast- a formula for ... // can pep-up your spirits and relish the ... University, and author of the formula for Marks & Spencer, ... open a champagne bottle. According to smith, P = T/4.5 ...
... difficult acrobatic stunts and are paying the price with a ... ,Cheerleaders catapult in the air, climb human ... the ground. They also make it to the emergency room. ... Pediatrics estimates that 208,800 young people aged 5 to 18 ...
... that is mainly present in pain relievers. Recently there is ... // clinicians complaining about over dosage of Acetaminophen. ... 50% of these cases are unintentional. Drugs like Tylenol, Benadryl, ... as one of the main composition in them. ...
... smokers or those who have been smoking in the past have ... tomography (CT scan) to detect // lung cancer if any, ... effective treatment and thereby improve the prognosis. ,The ... family history of the dreadful disease. For those of you ...
Cached Medicine News:Health News:Radiology advance points way to non-invasive brain cancer treatment 2Health News:Surroundings Have An Effect On Weight 2Health News:Cheerleaders run high risk of injury-US study 2Health News:Painkillers Lead To Liver Failure 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2
... navigation for Spine is ... integrate C-arm fluoroscopy with ... 3500 - spine Multi-application ... for ENT, cranial and ...
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... Mx8000 is a family of multislice CT ... version, Mx8000 also is available in an ... the same friendly user interface, advanced applications ... Both Dual and Quad systems can be ...
... 16 is Philips premium 16-slice CT scanner. ... to automatically delivering high quality, advanced results, the ... a platform that has been the most popular ... comprehensive organ assessment literally within seconds, and with ...
Medicine Products: